Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca

Clinical Trial Summary

This is a Phase 3 study comparing the efficacy, safety and tolerability of moxidectin and ivermectin in subjects infected with Onchocerca volvulus, which is the parasite that causes river blindness. Subjects participating in the study will be randomly assigned (by a 2 to1 ratio) to receive one orally-administered dose of either moxidectin or ivermectin.

See also
Status	Clinical Trial	Phase
Completed	`NCT00300768` - Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection	Phase 2
Not yet recruiting	`NCT04035174` - Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa	N/A
Recruiting	`NCT03653975` - Clinical Features and Potential Etiology of Epilepsy and Nodding Syndrome in the Mahenge Area, Ulanga District
Completed	`NCT03052998` - Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy	Phase 4
Active, not recruiting	`NCT04311671` - Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole	Phase 3
Active, not recruiting	`NCT03876262` - Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis	Phase 3
Terminated	`NCT04913610` - Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection	Phase 2
Completed	`NCT03962062` - A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years	Phase 1
Completed	`NCT01905436` - Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia
Recruiting	`NCT00001230` - Host Response to Infection and Treatment in Filarial Diseases
Completed	`NCT05750043` - Effect of Onchocerciasis Elimination Measures on the Incidence of Epilepsy in Maridi, South Sudan
Completed	`NCT05749653` - Impact of a Bi-annual CDTI on the Incidence of Epilepsy in an Onchocerciasis-endemic Area	N/A
Completed	`NCT02078024` - Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana	Phase 3
Completed	`NCT00127504` - Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness	Phase 2
Completed	`NCT03131401` - Prevalence of LF Infection in Districts Not Included in LF Control Activities
Completed	`NCT02032043` - Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast)
Completed	`NCT04188301` - Safety and Efficacy of IDA for Onchocerciasis	Phase 2
Terminated	`NCT05084560` - Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug	Phase 1
Completed	`NCT03517462` - Ocular Changes After Ivermectin - (DOLF IVM/Oncho)	N/A
Active, not recruiting	`NCT05180461` - Emodepside Phase II Trial for Treatment of Onchocerciasis	Phase 2

NCT number	NCT00790998
Study type	Interventional
Source	Medicines Development Limited
Contact
Status	Completed
Phase	Phase 3
Start date	April 2009
Completion date	May 2012

Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms